13 October 2021 - The approval is based on data from the Phase 3 IKEMA trial.
Sanofi Canada is pleased to announce that Health Canada has approved Sarclisa in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.